Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis. / Grøndahl, Magnus F. G.; Lange, Andreas H.; Suppli, Malte P.; Bagger, Jonatan I.; Thing, Mira; Gluud, Lise L.; Kofod, Dea H.; Hornum, Mads; Van Hall, Gerrit; Trammell, Samuel A. J.; Grevengoed, Trisha J.; Hartmann, Bolette; Holst, Jens J.; Vilsbøll, Tina; Christensen, Mikkel B.; Lund, Asger B.; Knop, Filip K.

I: Diabetes, 2024.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Grøndahl, MFG, Lange, AH, Suppli, MP, Bagger, JI, Thing, M, Gluud, LL, Kofod, DH, Hornum, M, Van Hall, G, Trammell, SAJ, Grevengoed, TJ, Hartmann, B, Holst, JJ, Vilsbøll, T, Christensen, MB, Lund, AB & Knop, FK 2024, 'Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis', Diabetes. https://doi.org/10.2337/db24-0305

APA

Grøndahl, M. F. G., Lange, A. H., Suppli, M. P., Bagger, J. I., Thing, M., Gluud, L. L., Kofod, D. H., Hornum, M., Van Hall, G., Trammell, S. A. J., Grevengoed, T. J., Hartmann, B., Holst, J. J., Vilsbøll, T., Christensen, M. B., Lund, A. B., & Knop, F. K. (Accepteret/In press). Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis. Diabetes. https://doi.org/10.2337/db24-0305

Vancouver

Grøndahl MFG, Lange AH, Suppli MP, Bagger JI, Thing M, Gluud LL o.a. Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis. Diabetes. 2024. https://doi.org/10.2337/db24-0305

Author

Grøndahl, Magnus F. G. ; Lange, Andreas H. ; Suppli, Malte P. ; Bagger, Jonatan I. ; Thing, Mira ; Gluud, Lise L. ; Kofod, Dea H. ; Hornum, Mads ; Van Hall, Gerrit ; Trammell, Samuel A. J. ; Grevengoed, Trisha J. ; Hartmann, Bolette ; Holst, Jens J. ; Vilsbøll, Tina ; Christensen, Mikkel B. ; Lund, Asger B. ; Knop, Filip K. / Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis. I: Diabetes. 2024.

Bibtex

@article{1a219804c9004625a486742e2100bb72,

title = "Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis",

abstract = "It is not completely clear which organs are responsible for glucagon elimination in humans, and disturbances in the elimination of glucagon could contribute to the hyperglucagonemia observed in chronic liver disease and chronic kidney disease (CKD). Here, we evaluated kinetics and metabolic effects of exogenous glucagon in individuals with stage 4 CKD (n =16), individuals with Child-Pugh A-C cirrhosis (n = 16) and matched control individuals (n = 16), before, during and after a 60-minute glucagon infusion (4 ng/kg/min). Individuals with CKD exhibited a significantly lower mean metabolic clearance rate of glucagon (14.0 [95% CI 12.2;15.7] mL/kg/min) both compared to individuals with cirrhosis (19.7 [18.1;21.3] mL/kg/min, P < 0.001) and to control individuals (20.4 [18.1;22.7] mL/kg/min, P < 0.001). Glucagon half-life was significantly prolonged in the CKD group (7.5 [6.9;8.2] minutes) compared to individuals with cirrhosis (5.7 [5.2;6.3] minutes, P = 0.002) and control individuals (5.7 [5.2;6.3] minutes, P < 0.001). No difference in the effects of exogenous glucagon on plasma glucose, amino acids, or triglycerides was observed between groups. In conclusion, chronic kidney disease, but not liver cirrhosis leads to a significant reduction in glucagon clearance, supporting the kidneys as a primary site for human glucagon elimination.",

author = "Gr{\o}ndahl, {Magnus F. G.} and Lange, {Andreas H.} and Suppli, {Malte P.} and Bagger, {Jonatan I.} and Mira Thing and Gluud, {Lise L.} and Kofod, {Dea H.} and Mads Hornum and {Van Hall}, Gerrit and Trammell, {Samuel A. J.} and Grevengoed, {Trisha J.} and Bolette Hartmann and Holst, {Jens J.} and Tina Vilsb{\o}ll and Christensen, {Mikkel B.} and Lund, {Asger B.} and Knop, {Filip K.}",

note = "{\textcopyright} 2024 by the American Diabetes Association.",

year = "2024",

doi = "10.2337/db24-0305",

language = "English",

journal = "Diabetes",

issn = "0012-1797",

publisher = "American Diabetes Association",

}

RIS

TY - JOUR

T1 - Glucagon Clearance is Decreased in Chronic Kidney Disease, but Preserved in Liver Cirrhosis

AU - Grøndahl, Magnus F. G.

AU - Lange, Andreas H.

AU - Suppli, Malte P.

AU - Bagger, Jonatan I.

AU - Thing, Mira

AU - Gluud, Lise L.

AU - Kofod, Dea H.

AU - Hornum, Mads

AU - Van Hall, Gerrit

AU - Trammell, Samuel A. J.

AU - Grevengoed, Trisha J.

AU - Hartmann, Bolette

AU - Holst, Jens J.

AU - Vilsbøll, Tina

AU - Christensen, Mikkel B.

AU - Lund, Asger B.

AU - Knop, Filip K.

PY - 2024

Y1 - 2024

N2 - It is not completely clear which organs are responsible for glucagon elimination in humans, and disturbances in the elimination of glucagon could contribute to the hyperglucagonemia observed in chronic liver disease and chronic kidney disease (CKD). Here, we evaluated kinetics and metabolic effects of exogenous glucagon in individuals with stage 4 CKD (n =16), individuals with Child-Pugh A-C cirrhosis (n = 16) and matched control individuals (n = 16), before, during and after a 60-minute glucagon infusion (4 ng/kg/min). Individuals with CKD exhibited a significantly lower mean metabolic clearance rate of glucagon (14.0 [95% CI 12.2;15.7] mL/kg/min) both compared to individuals with cirrhosis (19.7 [18.1;21.3] mL/kg/min, P < 0.001) and to control individuals (20.4 [18.1;22.7] mL/kg/min, P < 0.001). Glucagon half-life was significantly prolonged in the CKD group (7.5 [6.9;8.2] minutes) compared to individuals with cirrhosis (5.7 [5.2;6.3] minutes, P = 0.002) and control individuals (5.7 [5.2;6.3] minutes, P < 0.001). No difference in the effects of exogenous glucagon on plasma glucose, amino acids, or triglycerides was observed between groups. In conclusion, chronic kidney disease, but not liver cirrhosis leads to a significant reduction in glucagon clearance, supporting the kidneys as a primary site for human glucagon elimination.

AB - It is not completely clear which organs are responsible for glucagon elimination in humans, and disturbances in the elimination of glucagon could contribute to the hyperglucagonemia observed in chronic liver disease and chronic kidney disease (CKD). Here, we evaluated kinetics and metabolic effects of exogenous glucagon in individuals with stage 4 CKD (n =16), individuals with Child-Pugh A-C cirrhosis (n = 16) and matched control individuals (n = 16), before, during and after a 60-minute glucagon infusion (4 ng/kg/min). Individuals with CKD exhibited a significantly lower mean metabolic clearance rate of glucagon (14.0 [95% CI 12.2;15.7] mL/kg/min) both compared to individuals with cirrhosis (19.7 [18.1;21.3] mL/kg/min, P < 0.001) and to control individuals (20.4 [18.1;22.7] mL/kg/min, P < 0.001). Glucagon half-life was significantly prolonged in the CKD group (7.5 [6.9;8.2] minutes) compared to individuals with cirrhosis (5.7 [5.2;6.3] minutes, P = 0.002) and control individuals (5.7 [5.2;6.3] minutes, P < 0.001). No difference in the effects of exogenous glucagon on plasma glucose, amino acids, or triglycerides was observed between groups. In conclusion, chronic kidney disease, but not liver cirrhosis leads to a significant reduction in glucagon clearance, supporting the kidneys as a primary site for human glucagon elimination.

U2 - 10.2337/db24-0305

DO - 10.2337/db24-0305

M3 - Journal article

C2 - 39052774

JO - Diabetes

JF - Diabetes

SN - 0012-1797

ER -

ID: 399666569